Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 4/20 | 0.43 |
| ▸ | BRD4 | O60885 | 5/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.41 |
| ▸ | MTOR | P42345 | 7/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.38 |
| ▸ | TAF1 | P21675 | 1/20 | 0.38 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25852375 | 0.90 | METAP2 (0.42) | METAP2BRD4CACNA1BPIK3CAMTOR | |
| SCHEMBL23798962 | 0.89 | METAP2 (0.42) | METAP2BRD4CACNA1BPIK3CAMTOR | |
| SCHEMBL25091529 | 0.84 | BRD4 (0.44) | METAP2BRD4BRD9TAF1 | |
| SCHEMBL25091776 | 0.84 | CACNA1B (0.44) | BRD4CACNA1BPIK3CAMTORBRD9 | |
| SCHEMBL25844193 | 0.81 | BRD4 (0.44) | METAP2BRD4MTORBRD9TAF1 | |
| SCHEMBL25091094 | 0.80 | BRD4 (0.42) | METAP2BRD4PIK3CAMTORBRD9 | |
| SCHEMBL25091765 | 0.78 | BRD4 (0.42) | METAP2BRD4PIK3CAMTORBRD9 | |
| SCHEMBL23797638 | 0.77 | BRD4 (0.44) | BRD4CACNA1BBRD9CYP3A4 | |
| SCHEMBL25851626 | 0.76 | CYP3A4 (0.45) | BRD4CACNA1BPIK3CAMTORBRD9 | |
| SCHEMBL25844107 | 0.76 | CACNA1B (0.46) | BRD4CACNA1BBRD9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | METAP2 2721/4885BRD4 30/4885CACNA1B 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.